주식/증권
📈 긍정적
Why This Drugmaker’s Earnings Guidance Cut Doesn’t Tell the Full Story
요약
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.